Provided by Tiger Trade Technology Pte. Ltd.

HIGHTIDE-B

3.140
+0.2809.79%
Volume:534.00K
Turnover:1.64M
Market Cap:1.79B
PE:-5.31
High:3.200
Open:2.900
Low:2.900
Close:2.860
52wk High:4.720
52wk Low:1.800
Shares:571.00M
HK Float Shares:571.00M
Volume Ratio:0.76
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.591
ROE:-58.85%
ROA:-25.15%
PB:5.04
PE(LYR):-5.31
PS:45.21

Loading ...

HighTide Therapeutics Sets 29 June 2026 AGM; Seeks 20% Issue Mandate and 10% Buy-back Authority

Bulletin Express
·
Jun 02

HighTide Therapeutics (HIGHTIDE-B) Maintains Stable Share Base and Meets HKEX Public-Float Rule in May 2026

Bulletin Express
·
Jun 01

Brand Engagement Network signs five-year exclusive Africa reseller deal with Accelevate

Reuters
·
May 18

HighTide Therapeutics Announces Updated Board Composition and Committee Line-up

Bulletin Express
·
May 04

HighTide Therapeutics files directors list with Hong Kong Stock Exchange

Reuters
·
May 04

HIGHTIDE-B Appoints Chen Mingyu as Independent Non-Executive Director

Stock News
·
May 04

HighTide Therapeutics appoints Chen Mingyu as independent director, audit committee chair

Reuters
·
May 04

HIGHTIDE-B聚焦CKM创新研发,2025年亏损大幅收窄至人民币2.321亿元

Bulletin Express
·
Apr 29

HighTide Therapeutics publishes 2025 annual report

Reuters
·
Apr 29

HighTide Therapeutics Agrees to Lend HK$15 Million to CEO

MT Newswires Live
·
Apr 28

BRIEF-Hightide Therapeutics Enters Loan Agreement Up To HK$15 Million

Reuters
·
Apr 27

HighTide Therapeutics Inc - Enters Loan Agreement up to HK$15 Mln on April 27, 2026

THOMSON REUTERS
·
Apr 27

HighTide Therapeutics Reports No Change in Share Capital for March 2026; Public Float Remains Compliant

Bulletin Express
·
Apr 01

HighTide narrows 2025 loss to RMB232.10 million as R&D spending halves; HTD1801 NDA accepted

Bulletin Express
·
Mar 27

HIGHTIDE-B Reports Annual Results: Shareholder Loss Narrows to 245 Million Yuan

Stock News
·
Mar 27

Hightide Therapeutics FY2025 net loss narrows 39.2% to RMB232 million; other income drops 72.1% to RMB19 million

Reuters
·
Mar 27

HighTide Therapeutics Inc - FY Loss Attributable RMB245 Mln

THOMSON REUTERS
·
Mar 27

HighTide Therapeutics-B (2511) Schedules 27 March 2026 Board Meeting to Approve FY 2025 Audited Results

Bulletin Express
·
Mar 13

HighTide Therapeutics Gets China Acceptance for Type 2 Diabetes Mellitus Drug

MT Newswires Live
·
Mar 10

BRIEF-HighTide Therapeutics Says NMPA China Accepts New Drug Application For HTD1801

Reuters
·
Mar 10